Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FTC Chairman To Be Jon Leibowitz: Will Reverse Payments Get More Scrutiny?

Executive Summary

Jon Leibowitz, a fierce opponent of reverse settlements between brand name and generic companies, is set to head the Federal Trade Commission

You may also be interested in...

The End Of Pay-For-Delay? FTC Sees An Opportunity In AndroGel Lawsuit

Reverse payment settlements are a popular tactic for settling patent disputes between brand companies and their generic competitors. The Federal Trade Commission has aggressively (but mostly unsuccessfully) fought “pay-for-delay” deals in the courts, arguing that they drive up drug prices. Now FTC has its best chance yet at convincing the Supreme Court to hear the issue. Is this the end of pay-for-delay?

Brand/Generic Settlements Return To Capitol Hill

Apotex could make its case for scrapping first-to-file exclusivity during a hearing in Rep. Rush’s subcommittee.

Politics Of Mega-Mergers: Health Reform And U.S. Biopharma Realignment

One theme tying together the two mega-mergers announced so far in 2009 is the sense that biopharma companies are taking defensive measures to prepare for health care reform in the U.S

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts